Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00505713 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Study Using Rexin-G for Sarcoma

A Phase 1 study of Sarcoma, sponsored by Epeius Biotechnologies.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
2
Study locations

NCT00505713 is a Phase 1 study of Sarcoma that has completed, run by Epeius Biotechnologies. The registered enrollment target is 36 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00505713, a Phase 1 study of Sarcoma, has completed, sponsored by Epeius Biotechnologies.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
2
Study locations

Study Summary

Rexin-G is a tumor-targeted (pathotropic or disease-seeking) nanoparticle that when injected intravenously, seeks out and accumulates in cancerous lesions, thus enhancing local drug concentration within tumors. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.

Conditions Studied

Sarcoma

Interventions

  • GENETIC Rexin-G

Study Locations (2)

California

  • Epeius Clinical Research Unit - San Marino
  • Sarcoma Oncology Center - Santa Monica

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2007-07
Est. Completion 2011-06
Phase Phase 1

Sponsor

Epeius Biotechnologies

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00505713

The ClinicalTrials.gov registry entry for NCT00505713 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The listed sponsor is Epeius Biotechnologies, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Rexin-G is the first listed.

NCT00505713 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00505713 about?

NCT00505713 is a clinical study titled "Safety and Efficacy Study Using Rexin-G for Sarcoma". Rexin-G is a tumor-targeted (pathotropic or disease-seeking) nanoparticle that when injected intravenously, seeks out and accumulates in cancerous lesions, thus enhancing local drug concentration within tumors. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to...

What is the current status of trial NCT00505713?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-07. Estimated completion is 2011-06.

What conditions does trial NCT00505713 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT00505713?

The interventions under investigation include: Rexin-G (GENETIC).

Who is sponsoring clinical trial NCT00505713?

This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00505713 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.